We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

4 hedge funds and large institutions have $4.15M invested in Intra-Cellular Therapies Inc. in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 389 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 395 → 4 (-391)

100% less capital invested

Capital invested by funds: $13.6B → $4.15M (-$13.6B)

100% less funds holding in top 10

Funds holding in top 10: 52 → 0 (-52)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 389

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
4
Holders Change
-391
Holders Change %
-98.99%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
-52
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
389
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$1.26B
2
BlackRock
BlackRock
New York
-$1.15B
3
PCM
Pentwater Capital Management
Florida
-$685M
4
HI
HBK Investments
Texas
-$578M
5
Norges Bank
Norges Bank
Norway
-$472M
Name Holding Trade Value Shares
Change 		Change in
Stake
SIMG
126
Sonora Investment Management Group
Arizona
– -$10.7M -80,763 Closed
Bank of Montreal
127
Bank of Montreal
Ontario, Canada
– -$10.6M -80,666 Closed
VanEck Associates
128
VanEck Associates
New York
– -$10.6M -80,052 Closed
Arrowstreet Capital
129
Arrowstreet Capital
Massachusetts
– -$10.5M -79,287 Closed
PCM
130
Prelude Capital Management
New York
– -$10.4M -79,142 Closed
AIMCA
131
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
– -$10.4M -79,000 Closed
KI
132
Kapitalo Investimentos
Brazil
– -$10.4M -78,586 Closed
Macquarie Group
133
Macquarie Group
Australia
– -$9.82M -74,474 Closed
SCM
134
SCS Capital Management
Massachusetts
– -$9.6M -72,743 Closed
SFI
135
Susquehanna Fundamental Investments
Pennsylvania
– -$9.49M -71,973 Closed
NYLIM
136
New York Life Investment Management
New York
– -$9.47M -71,800 Closed
BFM
137
Boothbay Fund Management
New York
– -$8.42M -63,819 Closed
JPMIA
138
J.P. Marvel Investment Advisors
Massachusetts
– -$8.41M -63,771 Closed
Ohio Public Employees Retirement System (OPERS)
139
Ohio Public Employees Retirement System (OPERS)
Ohio
– -$8.34M -63,192 Closed
AG
140
Algert Global
California
– -$7.88M -59,701 Closed
VI
141
Versor Investments
New York
– -$7.47M -56,656 Closed
New York State Common Retirement Fund
142
New York State Common Retirement Fund
New York
– -$7.37M -55,855 Closed
EPM
143
Equitec Proprietary Markets
Illinois
– -$7.27M -55,100 Closed
AC
144
Athos Capital
Hong Kong
– -$7.26M -55,000 Closed
AGM
145
Alpine Global Management
New York
– -$6.6M -50,000 Closed
EIM
146
Essex Investment Management
Massachusetts
– -$6.56M -49,717 Closed
Barclays
147
Barclays
United Kingdom
– -$6.46M -49,003 Closed
PAS
148
Point72 Asia (Singapore)
Singapore
– -$6.43M -48,720 Closed
ACM
149
ADAR1 Capital Management
Texas
– -$6.34M -48,044 Closed
Treasurer of the State of North Carolina
150
Treasurer of the State of North Carolina
North Carolina
– -$6.21M -47,100 Closed
4 5
6
7 8

ITCI Hedge Fund Activity: Q2 2025 in Review

4 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2025, worth a combined $4.15M — down 100% from $13.6B a quarter earlier.

Sellers outnumbered buyers: 389 funds closed out of ITCI and 0 opened new positions — a net loss of 389 holders — while 2 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $1.26B sold.

  • 4 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2025, down from 395 in Q1 2025.
  • Funds reported $4.15M of Intra-Cellular Therapies Inc. stock for Q2 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2025 and 389 closed out, a net change of -389 holders.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2025 was Vanguard Group, an estimated $1.26B sold.

Based on aggregated 13F filings for Q2 2025.